Skip to content

Galectin-3: A Therapeutic Target for Cancer and Tissue Fibrosis

Researchers at the University of Liverpool have discovered two synthetic compounds as strong galectin-3 binding inhibitors.

Published: 28th September 2020
Galectin-3: A Therapeutic Target for Cancer and Tissue Fibrosis
K2 inhibits galectin-3-mediated tumour cell metastatic spread in mice (source: University of Liverpool)